MSD Technology Platform - Meso Scale
for biomarkers of drug-induced toxicity in conjunction with the Critical Path Initiative (C-Path) and Health and Environmental Sciences (HESI) consortia. MSD assays for cardiac markers are positive for cardiac homogenates and negative for others, whereas skeletal marker assays are positive for skeletal muscle only
Download MSD Technology Platform - Meso Scale
Information
Domain:
Source:
Link to this page:
Documents from same domain
Proinflammatory Panel 1 (human) Kits - Meso Scale
www.mesoscale.comHuman interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor (CSIF), is a 20.5 kDa, glycosylated homodimeric cytokine with two disulfide bonds. It is produced by a variety of cell lines such as T-cells, macrophages, and mast cells.The
MSD GOLD SULFO-TAG NHS-Ester
www.mesoscale.comThe challenge ratio is the number of moles of MSD GOLD SULFO-TAG per mole of protein in the conjugation reaction mixture. The challenge ratio required to achieve a specific conjugation ratio depends on a number of factors including pH, temperature, protein concentration, protein size and the number of lysines ava, ilable for coupling.
Related documents
Laboratory Diagnosis of Acute Myocardial Infarction
tru.uni-sz.bgon cardiac biomarkers, especially cardiac troponins [4, 20]. Troponin is a complex of three proteins on the thin filaments of skeletal and cardiac muscle fibres. During muscle contraction the . RUSEVA A. 10 Trakia Journal of Sciences, Vol. 3, No. 1, 2005
Pulmonary Embolism Diagnosis & Treatment Guideline ...
wa.kaiserpermanente.orgstrain on CTPA, or increased cardiac biomarkers (troponin or brain natriuretic peptide) levels. • Patient is expected to be compliant with treatment. • Patient feels well enough to be treated at home. • Patient has a Pulmonary Embolism Severity Index (PESI) score of < 85: Pulmonary Embolism Severity Index (PESI) Predictor Points
GET WITH THE GUIDELINES - American Heart Association
www.heart.orgCardiac Nurse Practitioner/Heart Failure Coordinator Englewood, CO . Outline ... Use of clinical risk-prediction tools and/or biomarkers to identify patients at higher risk for post-discharge clinical events are reasonable (Level of Evidence: B) Goals of follow-up appointment
Troponin fact sheet for Primary Care
www.nbt.nhs.ukc-Troponin T and c-Troponin I are specific cardiac structural proteins. If there is myocyte injury Troponin will be released. It does not indicate the mechanism of the myocyte injury. High sensitivity Troponin assays allow precise measurement at very low concentrations. High sensitivity assays are the biomarkers of choice.